American Technion Society

Cancer Patients May Not Have Higher COVID-19 Risk

17-Sep-2020 2:05 PM EDT, by American Technion Society

Newswise — A first-of-its-kind study examining the assumption that cancer patients are an at-risk group for COVID-19 finds that these patients do not get infected any more than the general population and do not suffer from more severe disease symptoms. In fact, based on their findings, the researchers hypothesize that cancer treatments may affect the patients’ response to COVID19-induced "cytokine storm."

From the moment the COVID-19 pandemic broke out, medical teams around the world operated under the assumption that cancer patients were an at-risk group in terms of contracting the virus. Defining cancer patients as an at-risk group had far-reaching implications for their treatment - this without any prior scientific basis. Patients were afraid to seek treatment for fear of contracting the coronavirus in hospitals, and in some countries, guidelines were issued for postponing oncology treatments in certain situations.

A new study conducted by researchers at Rambam Medical Center and the Technion reveals surprising findings, namely that cancer patients may not be associated with the broad range of at-risk groups of people suffering from morbidities. The research was led by Professor Yuval Shaked, head of the Rappaport - Technion Integrated Cancer Center (R-TICC) and Professor Irit Ben Aharon, director of the Division of Oncology at Rambam and principal investigator at the R-TICC, in collaboration with Dr. Tal Goshen-Lago, head of the Translational Research Division of Oncology at Rambam. The findings were published in Cancers, in a special edition dealing with the impact of the coronavirus on cancer patients.

The study included 271 participants, including 164 cancer patients, who came to the Rambam Medical Center to receive ongoing treatment for their disease, and a control group of 107 healthy employees among the medical staff. In the study, which was conducted between March and June 2020, all participants underwent blood tests, at three different times, to examine changes in the profile of the immune system. The test monitored three antibodies - IgG, IgM and IgA - that represent antibody formation at different times of virus exposure.

“We were surprised to find that cancer patients and health subjects developed antibodies at similar rates,” said Prof. Ben Aharon. "2.4% of cancer patients who participated in the study and 1.9% of participants in the healthy control group developed antibodies for the coronavirus and all were asymptomatic. Moreover, throughout the entire study period, no symptomatic coronavirus patients were detected in the study population and among the general population of our oncology patients." According to Prof. Ben Aharon, the CyTOF technology was used to map immune system cells, and a significant difference was found between the immune profile of cancer patients who were positive for coronavirus antibodies and the immune profile of the positive staff members.

"Our hypothesis is that the different response of cancer patients to the disease is related to the fact that anti-cancer treatment changes the profile of the immune system,” said Prof. Shaked. “The myeloid cells, which are vital cells in the immune system, are severely damaged by the coronavirus. In the general population and in the medical staff that participated in the study, the virus reduces the rate of myeloid cells by about 90%; in cancer patients, however, it reduces them by only 50%. This fact gives cancer patients relative protection.”

Prof. Ben Aharon added that the hypothesis is that anti-cancer treatments may change the profile of the immune system and its function which may limit the ability of the coronavirus to induce severe inflammation in patients receiving these treatments. The researchers estimate that this is why the proportion of cancer patients with non-hematological malignancies who develop severe disease is relatively low compared to that of the general population according to the literature, and that severity may be affected by other comorbidities. The mechanism for this observation is being further explored nowadays.

The research was supported by the Israel Cancer Research Fund (ICRF) and the European Research Council (ERC grant).

Prof. Irit Ben Aharon is a doctor and researcher and head of the Oncology Department at the Rambam Health Care Campus.

Prof. Yuval Shaked is head of the Technion Integrated Cancer Center in the Rappaport Faculty of Medicine (R-TICC). The center, established in 2016, promotes research that combines basic, clinical and engineering science in favor of developing new tools for cancer diagnosis, treatment and follow-up.

For more than a century, the Technion – Israel Institute of Technology has pioneered in science and technology education and delivered world-changing impact. Proudly a global university, the Technion has long leveraged boundary-crossing collaborations to advance breakthrough research and technologies. Now with a presence in three countries, the Technion will prepare the next generation of global innovators. Technion people, ideas and inventions make immeasurable contributions to the world, innovating in fields from cancer research and sustainable energy to quantum computing and computer science to do good around the world.

The American Technion Society supports visionary education and world-changing impact through the Technion – Israel Institute of Technology. Based in New York City, we represent thousands of US donors, alumni and stakeholders who invest in the Technion’s growth and innovation to advance critical research and technologies that serve the State of Israel and the global good. Over more than 75 years, our nationwide supporter network has funded new Technion scholarships, research, labs, and facilities that have helped deliver world-changing contributions and extend Technion education to campuses in three countries.

SEE ORIGINAL STUDY



Filters close

Showing results

110 of 6074
Newswise: Connect Chicago Initiative Expands Community COVID-19 Testing
Released: 27-Jul-2021 4:45 PM EDT
Connect Chicago Initiative Expands Community COVID-19 Testing
Rush University Medical Center

As COVID-19 cases rise in the U.S., Connect Chicago — new initiative between the Chicago Department of Public Health, Rush University Medical Center, and Esperanza Health Centers — is aiming to redouble testing efforts in Chicago communities that need it most.

Newswise: California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term
Released: 27-Jul-2021 1:35 PM EDT
California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term
California State University (CSU) Chancellor's Office

California State University to Implement COVID-19 Vaccination Requirement for Fall 2021 Term

Released: 27-Jul-2021 12:55 PM EDT
Behind the COVID-19 Diagnostic for Testing Hundreds of People at a Time
The Fannie and John Hertz Foundation

Hertz Fellow Cameron Myhrvold and colleagues are advancing research that started long before the pandemic.

Released: 27-Jul-2021 12:35 PM EDT
T cell response not critical for immune memory to SARS-CoV-2 or recovery from COVID-19
American Society for Microbiology (ASM)

New research conducted in monkeys reveals that T cells are not critical for the recovery of primates from acute COVID-19 infections.

Released: 27-Jul-2021 11:45 AM EDT
mRNA Vaccinations vs COVID-19 Risk in Teens – Vaccinations are Safer
Case Western Reserve University

Case Western Reserve University researchers have demonstrated that the risk for myocarditis/pericarditis (heart inflammation) among male teens (12-17) diagnosed with COVID-19 is nearly 6 times higher than their combined risk following first and second doses of an mRNA COVID-19 vaccination. The risk for myocarditis/pericarditis among girls (ages 12-17) is 21 times greater from COVID-19 than from vaccines.

Released: 27-Jul-2021 9:45 AM EDT
Twitter Study Tracks Early Days of COVID-19 Pandemic in U.S.
Binghamton University, State University of New York

Researchers at Binghamton University, State University of New York studied Twitter communications to understand the societal impact of COVID-19 in the United States during the early days of the pandemic.

Released: 27-Jul-2021 9:45 AM EDT
A First Report of COVID-19 Orbital Involvement Is Reported in the Journal of Craniofacial Surgery
Wolters Kluwer Health: Lippincott

A severe skin infection in the orbital area (around the eye) may represent an unusual complication of COVID-19, according to a patient report published in The Journal of Craniofacial Surgery. The journal is published in the Lippincott portfolio by Wolters Kluwer.

Newswise: “Baiya Vaccine” from Chula — a Testament of Thai Mastery — Coming this September
Released: 27-Jul-2021 8:55 AM EDT
“Baiya Vaccine” from Chula — a Testament of Thai Mastery — Coming this September
Chulalongkorn University

Chula Pharmacy prepares to test “Baiya Vaccine” a Thai vaccine against COVID–19 by “Baiya Phytofarm“, a Chula startup. The vaccines have been produced at the first plant in Asia that manufactures plant–based vaccines for humans. Clinical trials with volunteers and the research for the second–generation vaccine to fight the virus variants are to commence in September 2021.


Showing results

110 of 6074

close
2.27322